Drugs /

quikin cd19-cart

Back to Drugs List
Associated Genetic Biomarkers

Overview

Clinical Trials

View Clinical Trials for quikin cd19-cart

Quikin cd19-cart has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating quikin cd19-cart, 1 is no phase specified (1 open).

CD19 Expression and EBV Negative are the most frequent biomarker inclusion criteria for quikin cd19-cart clinical trials.

Non-hodgkin lymphoma is the most common disease being investigated in quikin cd19-cart clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Quikin Cd19-Cart
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating quikin cd19-cart and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Categories [2]:
Immunotherapies
Drug Target(s) [2]:
CD19

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.